NYU Langone Health
New York, 10016, United States
Not Yet Recruiting
NCT Number: NCT07631858
Perspectives About Online Information
The purpose of this research study is to understand the perspectives of U.S. adults on online information about prostate cancer. Study participants will receive different online information about prostate cancer to view such as a video post or text post, and complete a one-time online survey that will take approximately 10 minutes.
Not Yet Recruiting
Trial opening soon.
Get NotifiedKey information
Conditions
Age range
40 year and older
Sex eligibility
All sexes
Study type
Interventional
Phase
Not applicable
Primary location
Who can participate
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
- U.S. adult age 40+ who identifies as Black and/or Hispanic
- Enrolled in Dynata online survey panel
- Willing and able to participate in the research study.
Exclusion criteria
- Individuals up to age 39
- Individuals living outside the U.S.
- Individuals who are not Black and/or Hispanic
Treatment and study plan
Post (video) about prostate cancer
OtherParticipants will review a post about prostate cancer.
Post (text post) about prostate cancer
OtherParticipants will review a post about prostate cancer.
Survey
OtherThe survey will include questions about demographics and internet use. It may also provide participants with resources about online information.
Primary outcomes
-
Trust in the post, as measured by a 4-point Likert scale
Time frame: Post-intervention (~5 minutes)
A single question is asked of "How much do you trust the information in the post?" Participants used a 4-point Likert scale from 1 (trust the information completely) to 4 (Did not trust the information). Scores range from 1-4, with higher scores indicating less trust.
Secondary outcomes
-
Short-form Positive and Negative Affect Schedule (PANAS) Positive Score
Time frame: Post-intervention (~5 minutes)
The Short-form Positive and Negative Affect Schedule (PANAS-SF) is a brief, 10-item psychometric tool used to assess two distinct emotional dimensions: Positive Affect (e.g., active, inspired) and Negative Affect (e.g., upset, afraid). Respondents rate each of the 10 adjectives on a 5-point Likert scale. Scores can range from 10 - 50, with higher scores representing higher levels of positive affect.
-
Short-form Positive and Negative Affect Schedule (PANAS) Negative Score
Time frame: Post-intervention (~5 minutes)
The Short-form Positive and Negative Affect Schedule (PANAS-SF) is a brief, 10-item psychometric tool used to assess two distinct emotional dimensions: Positive Affect (e.g., active, inspired) and Negative Affect (e.g., upset, afraid). Respondents rate each of the 10 adjectives on a 5-point Likert scale. Scores can range from 10 - 50, with lower scores representing lower levels of negative affect.
Study contacts
Contact information is provided by the study sponsor or research team.
Nataliya Byrne
CONTACT
Stacy Loeb, MD, MSc, PhD
CONTACT
Sponsors and collaborators
Lead sponsor
NYU Langone Health
Other
Collaborators
- National Cancer Institute (NCI)
Registry information
Important dates
- Study start
- 2026
- Primary completion
- 2028
- Study completion
- 2028
- First posted
- Jun 8, 2026
- Registry last updated
- Jun 8, 2026
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Related clinical trials
Published trials that share one or more normalized conditions with this study.
Not Yet Recruiting
Multitargeted Recombinant Ad5 PSA/MUC-1/Brachyury-Based Immunotherapy (TriAdeno) Vaccine With IL-15 Superagonist N-803 in Participants With Clinically Localized Prostate Cancer Undergoing Active Surveillance
NCT07574541
Adenocarcinoma, Carcinoma
Bethesda, Maryland, United States
View Trial Details
Not Yet Recruiting
IL-15 Superagonist With or Without Vaccine in Biochemically Recurrent Prostate Cancer After Previous Stereotactic Body Radiation Therapy
NCT07686380
Genital Diseases, Genital Diseases, Male
Bethesda, Maryland, United States
View Trial Details
Not Yet Recruiting
Docetaxel and SX-682 in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma, Salivary Gland Carcinoma, and Advanced Prostate Cancer
NCT07667400
Adenocarcinoma, Adenoid Cystic Carcinoma
Bethesda, Maryland, United States
View Trial Details
Not Yet Recruiting
LuX: Xaluritamig in Participants With Metastatic Castrate Resistant Prostate Cancer and Suboptimal Response to Lutetium 177 Vipivotide Tetraxetan
NCT07737925
Genital Diseases, Genital Diseases, Male
View Trial Details